10th European Congress on Tropical Medicine and International Health
The main objective of ECTMIH 2017 was to provide a platform for state-of-the-art updates and recent breakthroughs in the field of tropical medicine and global health.
DNDi presented on sleeping sickness, visceral leishmaniasis, mycetoma, and onchocerciasis.
Symposium
Phase II/III results for fexinidazole, the first oral treatment for human African trypanosomiasis (HAT)
Date: Tuesday, October 17, 2017
Organizer: Nathalie Strub Wourgaft, Medical Director, DNDi
| Introduction José Ramon Franco, WHO |
| Developing treatments for sleeping sickness: DNDi’s R&D strategy Nathalie Strub Wourgaft, Medical Director, DNDi |
| Results from the pivotal trial of fexinidazole: non-inferiority shown to the gold standard NECT Antoine Tarral, Head of HAT Clinical Program, DNDi |
| The efficacy of fexinidazole in children and stage 1 patients Clélia Bardonneau, Senior Clinical Project Manager HAT, DNDi |
Structured discussion 1: Working together across continents to organize and run clinical trials in remote areas |
Structured discussion 2: The potential impact of fexinidazole on the global strategy to eliminate sleeping sickness |
Oral Presentations
Hepatitis C care in resource-contained settings – do we have a scalable public health approach anno 2017?
Date: Wednesday, October 18, 2017
The innovative R&D model of the Drug for Neglected Diseases initiative (DNDi) to increase access to HCV care in low- and middle-income countries |
Kala-azar elimination in the Indian subcontinent
Date: Thursday, October 19, 2017
Phlebotomus argentipes Sand Fly control in Bangladesh: A cluster randomized controlled trial |
International Partnerships and Collaboration
Date: Thursday, October 19, 2017
Building a visceral leishmaniasis data-sharing platform to optimize treatment and inform future research |
Poster Sessions
Date: Tuesday, October 17, 2017
Clinical mentoring via mobile teams – a new approach to visceral leishmaniasis care in resource constrained settings in Africa |
Screening the pathogen box and the stasis box to identify compounds inhibiting Madurella mycetomatis growth in vitro and in vivo Lim W, Konings M, Melse Y, Todd M, Perry B, Ioset JR, van de Sande W |
Date: Wednesday, October 18, 2017
The Human African Trypanosomiasis (HAT) Platform / Plateforme Trypanosomiase Humaine Africaine (THA) |
Is long lasting insecticide treated bed net able to reduce visceral leishmaniasis incidence? The evidence in Bangladesh |
Projected number of people with onchocerciasis-loiasis co-infection in Africa, 1995-2025 |
Date: Thursday, October 19, 2017
Visceral leishmaniasis treatment access – The reality on the ground in Sudan |
More information:
